Coloplast A/S develops and markets intimate healthcare products and services worldwide.
Established dividend payer with proven track record.
Share Price & News
How has Coloplast's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: COLO B has not had significant price volatility in the past 3 months.
7 Day Return
DK Medical Equipment
1 Year Return
DK Medical Equipment
Return vs Industry: COLO B exceeded the Danish Medical Equipment industry which returned 17.9% over the past year.
Return vs Market: COLO B exceeded the Danish Market which returned 5.2% over the past year.
Price Volatility Vs. Market
How volatile is Coloplast's share price compared to the market and industry in the last 5 years?
Simply Wall St News
1 week ago | Simply Wall StIf You Had Bought Coloplast (CPH:COLO B) Shares Five Years Ago You'd Have Made 76%
1 month ago | Simply Wall StHow Does Coloplast A/S's (CPH:COLO B) Earnings Growth Stack Up Against The Industry?
1 month ago | Simply Wall StColoplast A/S Just Reported And Analysts Have Been Lifting Their Price Targets
Is Coloplast undervalued compared to its fair value and its price relative to the market?
Price to Earnings (PE) ratio
Share Price vs. Fair Value
Below Fair Value: COLO B (DKK988) is trading above our estimate of fair value (DKK887.09)
Significantly Below Fair Value: COLO B is trading above our estimate of fair value.
Price To Earnings Ratio
PE vs Industry: COLO B is poor value based on its PE Ratio (52.8x) compared to the Medical Equipment industry average (38.4x).
PE vs Market: COLO B is poor value based on its PE Ratio (52.8x) compared to the Danish market (12.8x).
Price to Earnings Growth Ratio
PEG Ratio: COLO B is poor value based on its PEG Ratio (5.4x)
Price to Book Ratio
PB vs Industry: COLO B is overvalued based on its PB Ratio (38.5x) compared to the DK Medical Equipment industry average (6.4x).
How is Coloplast forecast to perform in the next 1 to 3 years based on estimates from 18 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: COLO B's forecast earnings growth (9.8% per year) is above the savings rate (-0.3%).
Earnings vs Market: COLO B's earnings (9.8% per year) are forecast to grow slower than the Danish market (12.1% per year).
High Growth Earnings: COLO B's earnings are forecast to grow, but not significantly.
Revenue vs Market: COLO B's revenue (7.9% per year) is forecast to grow faster than the Danish market (6% per year).
High Growth Revenue: COLO B's revenue (7.9% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: COLO B's Return on Equity is forecast to be very high in 3 years time (63.5%).
How has Coloplast performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: COLO B has high quality earnings.
Growing Profit Margin: COLO B's current net profit margins (21.7%) are lower than last year (23.2%).
Past Earnings Growth Analysis
Earnings Trend: COLO B's earnings have grown by 16.2% per year over the past 5 years.
Accelerating Growth: COLO B's earnings growth over the past year (2%) is below its 5-year average (16.2% per year).
Earnings vs Industry: COLO B earnings growth over the past year (2%) exceeded the Medical Equipment industry -17.2%.
Return on Equity
High ROE: COLO B's Return on Equity (72.9%) is considered outstanding.
How is Coloplast's financial position?
Financial Position Analysis
Short Term Liabilities: COLO B's short term assets (DKK6.4B) do not cover its short term liabilities (DKK6.6B).
Long Term Liabilities: COLO B's short term assets (DKK6.4B) exceed its long term liabilities (DKK1.1B).
Debt to Equity History and Analysis
Debt Level: COLO B's debt to equity ratio (54.8%) is considered high.
Reducing Debt: COLO B's debt to equity ratio has increased from 6.8% to 54.8% over the past 5 years.
Debt Coverage: COLO B's debt is well covered by operating cash flow (154.4%).
Interest Coverage: COLO B earns more interest than it pays, so coverage of interest payments is not a concern.
What is Coloplast's current dividend yield, its reliability and sustainability?
Current Dividend Yield
Dividend Yield vs Market
Notable Dividend: COLO B's dividend (1.72%) is higher than the bottom 25% of dividend payers in the Danish market (1.7%).
High Dividend: COLO B's dividend (1.72%) is low compared to the top 25% of dividend payers in the Danish market (4.46%).
Stability and Growth of Payments
Stable Dividend: COLO B's dividends per share have been stable in the past 10 years.
Growing Dividend: COLO B's dividend payments have increased over the past 10 years.
Current Payout to Shareholders
Dividend Coverage: With its reasonable payout ratio (64.1%), COLO B's dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: COLO B's dividends in 3 years are forecast to be covered by earnings (85.7% payout ratio).
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Kristian Villumsen (49yo)
Mr. Kristian Villumsen has been the President and Chief Executive Officer of Coloplast A/S since December 4, 2018. Mr. Villumsen was an Executive Vice President of Chronic Care at Coloplast A/S since July ...
CEO Compensation Analysis
Compensation vs Market: Kristian's total compensation ($USD2.55M) is about average for companies of similar size in the Danish market ($USD3.18M).
Compensation vs Earnings: Kristian's compensation has increased by more than 20% in the past year.
|President & CEO||1.33yrs||ø17.50m||0.043% DKK89.6m|
|Executive VP & CFO||5.75yrs||ø9.90m||no data|
|Executive Vice President of Global Operations||5.75yrs||ø9.50m||0.00015% DKK315.0k|
|Executive Vice President of Chronic Care||1.25yrs||ø8.90m||no data|
|Senior Controller & Director||13.33yrs||ø450.00k||0.0019% DKK3.9m|
|Vice President of Investor Relations||3.5yrs||no data||no data|
|Director of Corporate Communications||no data||no data||no data|
|Senior Vice President of Wound Care||no data||no data||no data|
|Senior Vice President of Sales Europe||8yrs||no data||no data|
|Senior Vice President of Global R&D||7.33yrs||no data||no data|
Experienced Management: COLO B's management team is seasoned and experienced (5.8 years average tenure).
|Senior Controller & Director||13.33yrs||ø450.00k||0.0019% DKK3.9m|
|Independent Director||2.33yrs||ø634.00k||0.0028% DKK5.9m|
|Independent Director||12.33yrs||ø767.00k||0.0034% DKK7.2m|
|Chairman of the Board||1.33yrs||ø20.56m||0.098% DKK204.9m|
|Deputy Chairman||no data||ø910.00k||22.12% DKK46.5b|
|Independent Director||4.33yrs||ø532.00k||no data|
|Independent Director||4.33yrs||ø634.00k||0.000080% DKK168.0k|
Experienced Board: COLO B's board of directors are considered experienced (3.3 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Coloplast A/S's company bio, employee growth, exchange listings and data sources
- Name: Coloplast A/S
- Ticker: COLO B
- Exchange: CPSE
- Founded: 1954
- Industry: Health Care Supplies
- Sector: Healthcare
- Market Cap: ø209.991b
- Shares outstanding: 212.54m
- Website: https://www.coloplast.com
Number of Employees
- Coloplast A/S
- Holtedam 1-3
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|CLPB.F||OTCPK (Pink Sheets LLC)||Yes||Class B Shares||US||USD||Mar 1993|
|COLO B||CPSE (OMX Nordic Exchange Copenhagen)||Yes||Class B Shares||DK||DKK||Mar 1993|
|CBHD||DB (Deutsche Boerse AG)||Yes||Class B Shares||DE||EUR||Mar 1993|
|COLOBC||BATS-CHIXE (BATS 'Chi-X Europe')||Yes||Class B Shares||GB||DKK||Mar 1993|
|0QBO||LSE (London Stock Exchange)||Yes||Class B Shares||GB||DKK||Mar 1993|
|COLOB||SWX (SIX Swiss Exchange)||Yes||Class B Shares||CH||CHF||Mar 1993|
|COLO||WBAG (Wiener Boerse AG)||Yes||Class B Shares||AT||EUR||Mar 1993|
|0QBO N||BMV (Bolsa Mexicana de Valores)||Yes||Class B Shares||MX||MXN||Mar 1993|
|CLPB.Y||OTCPK (Pink Sheets LLC)||UNSPONSORD ADR||US||USD||Nov 2010|
Coloplast A/S develops and markets intimate healthcare products and services worldwide. It provides ostomy care products, including SenSura Mio, which provides fit to individual body shapes and optimal discretion for various types of ostomies; and SenSura Ostomy care solutions, as well as ostomy accessories under the Brava brand. The company also offers continence care products, such as SpeediCath catheters that offer catherisation for both genders; Peristeen, an anal irrigation system for controlled emptying of the bowels; and Conveen Active urine bags. In addition, it provides wound care products, such as foam dressings under the Biatain brand and hydrocolloid dressing under the Comfeel brand, as well as skin care products, such as bathing and cleansing products, moisturizers, skin protectants, antifungal products, hand cleanser, and odor control products. Further, the company develops, produces, and markets products for the surgical treatment of urological and gynecological disorders, such as urinary stone diseases, benign prostate hyperplasia, voiding dysfunctions, erectile dysfunction, and urinary incontinence. The company supplies its products to hospitals, institutions, wholesalers, and pharmacies; and directly to users. Coloplast A/S was founded in 1954 and is headquartered in Humlebæk, Denmark.
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2020/04/08 01:15|
|End of Day Share Price||2020/04/07 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.